Death receptor 5

Death receptor 5 (DR5), also known as TRAIL receptor 2 (TRAIL-R2) or TNF-related apoptosis-inducing ligand receptor 2 (TNFRSF10B), is a protein that in humans is encoded by the TNFRSF10B gene. DR5 is a member of the tumor necrosis factor receptor superfamily and plays a crucial role in the process of apoptosis.

Structure

DR5 is a type I transmembrane protein that contains an extracellular domain, a transmembrane domain, and an intracellular death domain. The extracellular domain is responsible for binding to its ligand, TRAIL (TNF-related apoptosis-inducing ligand), while the intracellular death domain is essential for transmitting apoptotic signals.

Function

DR5 is primarily involved in the induction of apoptosis. Upon binding to TRAIL, DR5 undergoes a conformational change that allows it to recruit adaptor proteins such as FADD (Fas-associated death domain) and procaspase-8. This recruitment leads to the formation of the death-inducing signaling complex (DISC), which subsequently activates caspase-8. Activated caspase-8 then initiates a cascade of downstream caspase activation, ultimately leading to cell death.

Role in Cancer

DR5 has been extensively studied for its role in cancer biology. Many tumor cells express high levels of DR5, making them susceptible to TRAIL-induced apoptosis. This has led to the development of therapeutic agents that target DR5 to selectively induce apoptosis in cancer cells. However, some cancer cells develop resistance to TRAIL-induced apoptosis through various mechanisms, including the downregulation of DR5 expression or the upregulation of anti-apoptotic proteins.

Clinical Significance

The expression levels of DR5 can serve as a prognostic marker in certain types of cancer. High levels of DR5 expression are often associated with a better prognosis and increased sensitivity to TRAIL-based therapies. Conversely, low levels of DR5 expression can indicate resistance to such therapies and a poorer prognosis.

Research and Therapeutics

Ongoing research is focused on enhancing the efficacy of DR5-targeted therapies. Strategies include the development of agonistic antibodies that mimic TRAIL, combination therapies that sensitize tumor cells to TRAIL, and the identification of biomarkers that predict response to DR5-targeted treatments.

Related Pages

• Apoptosis
• TRAIL
• Caspase
• Tumor necrosis factor receptor superfamily
• Cancer

See Also

• FADD
• Death-inducing signaling complex
• TNFRSF10B